Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR)

PHASE3CompletedINTERVENTIONAL
Enrollment

402

Participants

Timeline

Start Date

March 29, 2016

Primary Completion Date

August 6, 2018

Study Completion Date

July 16, 2019

Conditions
Nonproliferative Diabetic Retinopathy
Interventions
DRUG

Intravitreal aflibercept injection [IAI]

DRUG

Sham

Trial Locations (89)

1062

Regeneron Study Site, Budapest

1106

Regeneron Study Site, Budapest

4032

Regeneron Study Site, Debrecen

6720

Regeneron Study Site, Szeged

8900

Regeneron Study Site, Zalaegerszeg

18704

Regeneron Study Site, Kingston

19107

Regeneron Study Site, Philadelphia

21204

Regeneron Study Site, Baltimore

21209

Regeneron Study Siste, Baltimore

21287

Regeneron Study Site, Baltimore

21740

Regeneron Study Site, Hagerstown

22031

Regeneron Study Site, Fairfax

26506

Regeneron Study Site, Morgantown

28210

Regeneron Study Site, Charlotte

28803

Regeneron Study Site, Asheville

29169

Regeneron Study Site, West Columbia

29456

Regeneron Study Site, Ladson

29501

Regeneron Study Site, Florence

30060

Regeneron Study Ssites, Marietta

30084

Regeneron study Site, Tucker

32308

Regeneron Study Site, Tallahassee

32701

Regeneron Study Site, Altamonte Springs

32806

Regeneron Study Site, Orlando

32901

Regeneron Study Site, Melbourne

33064

Regeneron Study Site, Deerfield Beach

33126

Regeneron Study Site, Miami

33143

Regeneron Study Site, Miami

33324

Regeneron Study Site, Plantation

33612

Regeneron Study Site, Tampa

33770

Regeneron Study Site, Largo

33805

Regeneron Study Site, Lakeland

33880

Regeneron Study Site, Winter Haven

33912

Regeneron Study Site, Fort Myers

35043

Regeneron Study Site, Marburg

37203

Regeneron Study Site, Nashville

37232

Regeneron Study Site, Nashville

37421

Regeneron Study Site, Chattanooga

38138

Regeneron Study Site, Germantown

40509

Regeneron Study Site, Lexington

43212

Regeneron Study Site, Columbus

46290

Regeneron Study Site, Indianapolis

47150

Regeneron Study Site, New Albany

48145

Regeneron Study Site, Münster

57701

Regeneron Study Site, Rapid City

60452

Regeneron Study Site, Oak Forest

60612

Regeneron Study Site, Chicago

73104

Regeneron Study Site, Oklahoma City

75231

Regeneron Study Site, Dallas

76087

Regeneron Study Site, Willow Park

77030

Regeneron Study Site, Houston

77384

Regeneron Study Site, The Woodlands

78240

Regeneron Study Site, San Antonio

78559

Regeneron Study Site, Harlingen

78705

Regeneron Study Site 1, Austin

Regeneron Study Site 2, Austin

79606

Regeneron Study Site, Abilene

80401

Regeneron Study Site, Golden

80909

Regeneron Study Site, Colorado Springs

84132

Regeneron Study Site, Salt Lake City

85020

Regeneron Study Site, Phoenix

85704

Regeneron Study Site, Tucson

87109

Regeneron Study Site, Albuquerque

89052

Regeneron Study Site, Henderson

90211

Regeneron Study Site, Beverly Hills

91007

Regeneron Study Site, Arcadia

91436

Regeneron Study Site, Encino

92056

Regeneron Study Site, Oceanside

92093

Regeneron Study Site, La Jolla

92835

Regeneron Study Site, Fullerton

94040

Regeneron Study Site, Mountain View

94609

Regeneron Study Site, Oakland

95841

Regeneron Study Site, Sacramento

97504

Regeneron Study Site, Medford

99204

Regeneron Study Site, Spokane

06320

Regeneron Study Site, New London

02114

Regeneron Study Site, Boston

07003

Regeneron Study Site, Bloomfield

05401

Regeneron Study Site, Burlington

04103

Regeneron Study Site, Leipzig

078-8510

Regeneron Study Site, Asahikawa

660-8550

Regeneron Study Site, Amagasaki

390-8621

Regeneron Study Site, Matsumoto

101-8309

Regeneron Study Site, Chiyoda City

890-8520

Regeneron Study Site, Kagoshima

852-8501

Regeneron Study Site, Nagasaki

00613

Regeneron Study Site, Arecibo

00907

Regeneron Study Site, San Juan

GU16 7UJ

Regeneron Study Site, Camberley

EC1V 2PD

Regeneron Study Site, London

All Listed Sponsors
lead

Regeneron Pharmaceuticals

INDUSTRY

NCT02718326 - Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) | Biotech Hunter | Biotech Hunter